Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos (Nasdaq: ALGS) appointed James Hassard, MBA as Executive Vice President, Chief Commercial Officer effective January 13, 2026. Mr. Hassard will build and lead Aligos' global commercial capabilities and join the senior leadership team as the company plans for late‑stage development of pevifoscorvir sodium while progressing the Phase 2 B‑SUPREME study. He previously served as chief commercial officer at Crinetics and Arrowhead and held roles at Coherus Oncology, Amgen and Merck, with global experience in the US, Canada and Europe. Hassard holds a BSc in Pharmacology (University of Toronto) and an MBA (Nova Southeastern University).
Aligos Therapeutics (Nasdaq: ALGS) announced that its Compensation Committee granted non-qualified stock options to purchase an aggregate of 14,100 shares as inducement awards to newly hired employees on Dec 9, 2025. The awards were granted under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price of Aligos common stock on the grant date and vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS) presented positive data at HEP-DART 2025 (Dec 7–11, 2025). Oral presentations covered 96-week and post-treatment follow-up data from a Phase 1 pevifoscorvir sodium monotherapy study in chronic HBV and new in vivo ALG-055009 data showing synergistic weight and fat-mass loss when combined with incretin receptor agonists.
In diet-induced obese mice, semaglutide (SEMA) produced a maximum 23.9% weight loss vs 33% for SEMA+ALG-055009 (additional 8.6%); tirzepatide (TIRZEP) monotherapy reached 27.1%–34.4% vs 39%–40% for TIRZEP+ALG-055009 (additional 5.8%–11.7%). Presentations also included early HBV and HDV ASO program posters.
Aligos Therapeutics (Nasdaq: ALGS) announced inducement equity awards granted by its Compensation Committee on Nov 11, 2025 to newly hired employees. An aggregate of 23,600 non-qualified stock options were granted under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing stock price on the grant date and vest over four years with 25% vesting after one year and the remainder monthly thereafter, subject to continued employment.
Aligos Therapeutics (NASDAQ: ALGS) presented positive clinical and preclinical data for pevifoscorvir sodium (ALG-000184) and its active moiety ALG-001075 at The Liver Meeting® 2025 (Nov 7–11, 2025).
Key clinical results: in Phase 1 monotherapy, 300 mg daily pevifoscorvir produced rapid, durable HBV DNA suppression with 100% (10/10) HBeAg+ subjects
Aligos Therapeutics (Nasdaq: ALGS) reported Q3 2025 business progress and financials on Nov 6, 2025. Pevifoscorvir sodium Phase 2 B-SUPREME began dosing (first patient Aug 2025) in ~200 untreated chronic HBV subjects across the U.S., China, Hong Kong, and Canada; interim readouts are projected in 1H and 2H 2026 with topline in 2027. Phase 1 post-treatment data (96 weeks dosing) will be presented at The Liver Meeting 2025.
Cash plus investments were $99.1M at Sept 30, 2025, funding planned operations into Q3 2026. Q3 net loss was $31.5M (loss per share $(3.04)); R&D expense was $23.9M. Company is evaluating funding options including potential out-licensing for continued development.
Aligos Therapeutics (Nasdaq: ALGS) announced management will present at two investor conferences in late 2025: a Jefferies London Healthcare Conference fireside chat on November 17, 2025 at 3:00 PM GMT and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 3, 2025 at 2:00 PM ET.
Both presentations will premiere at the listed times and are accessible via the Presentation & Events section on Aligos’ Investors page at www.aligos.com. A replay of each webcast will be available for at least 30 days following the presentation.
Aligos Therapeutics (Nasdaq: ALGS) will release its third quarter 2025 financial results on Thursday, November 6, 2025 before the U.S. market opens. The company is a clinical-stage biotech focused on therapies for liver and viral diseases. Investors can expect a routine pre-market earnings release and any accompanying commentary or webcast details to be announced separately.
Aligos Therapeutics (Nasdaq: ALGS) announced on Oct 17, 2025 that its Compensation Committee granted non-qualified stock options totaling 27,400 shares as inducement awards to newly hired employees, effective Oct 15, 2025.
The awards were made under the companys 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing price on the Grant Date and vest over four years with 25% vesting at the first anniversary and the remainder vesting in equal monthly installments, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS) announced that the USAN Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, an investigational therapy for chronic hepatitis B virus (HBV) infection. The name is intended to provide consistent identification and support international recognition and transparency.
The company said the name, shortened to “pevy,” is the first generic name assigned to a compound at Aligos and comes as the program advances through the ongoing Phase 2 B-Supreme study. The announcement highlights a regulatory-naming milestone rather than clinical readouts or approvals.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
